This report examines the industry perception of the EDC and eCOA/ePRO markets based on the responses of over 150 industry professionals experienced with these systems. ISR has asked respondents how their respective companies handle the decisions associated with outsourcing these systems as well as how they would prefer the outsourcing be handled. Additionally, ISR has benchmarked 22 EDC and 22 eCOA/ePRO systems based on 651 EDC and 432 ePRO service provider encounters. Each provider’s performance is evaluated and benchmarked based on the performance of these providers against expectations across 18-21 attributes.
Learn more: http://www.isrreports.com/product/edc-and-ecoaepro-market-dynamics-and-service-provider-performance-2015/
Presentation on the promises and pitfalls of applying Agile in a Quality Management System. How do you get the benefits of agile while maintaining quality and regulatory compliance?
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...Peter Dellva
BioTechLogic's Tracy TreDenick delivered a compelling presentation discussing process validation & regulatory strategies for Fast-Track and Breakthrough Therapies at BPI West - March 20, 2018
Usability Validation Testing of Medical Devices and SoftwareUXPA Boston
The U.S. FDA and international regulatory bodies require usability testing of medical devices, products, software, and systems as part of their overall validation. Manufacturers must demonstrate that all potential use-related hazards have been identified, prioritized, and mitigated. The method for demonstrating this is human factors/usability engineering (HF/UE) validation testing. However, the way we conduct these studies is in many ways different from the way we conduct studies of non-medical products and systems.
This topic is relevant to the Boston UX community given the convergence of consumer and medical devices, as well as the rise of wearable technologies and the apps that interact with them. This presentation will cover the key aspects of HF/UE validation (a.k.a. ‘summative’) testing and what the FDA expects in the final HF/UE summary report.
Importantly, this session will consist of half presentation and half Q&A, with the audience driving the discussion toward current issues, questions, and challenges that are relevant to them.
An brief introduction to the clinical data management process is described in this slides. These slides provides you the information regarding the data evaluation in the clinical trials , edit checks and data review finally data locking,then the data is submitted to the concerned regulatory body.
Presentation on the promises and pitfalls of applying Agile in a Quality Management System. How do you get the benefits of agile while maintaining quality and regulatory compliance?
Process Validation & Regulatory Strategies for Fast-track and Breakthrough Th...Peter Dellva
BioTechLogic's Tracy TreDenick delivered a compelling presentation discussing process validation & regulatory strategies for Fast-Track and Breakthrough Therapies at BPI West - March 20, 2018
Usability Validation Testing of Medical Devices and SoftwareUXPA Boston
The U.S. FDA and international regulatory bodies require usability testing of medical devices, products, software, and systems as part of their overall validation. Manufacturers must demonstrate that all potential use-related hazards have been identified, prioritized, and mitigated. The method for demonstrating this is human factors/usability engineering (HF/UE) validation testing. However, the way we conduct these studies is in many ways different from the way we conduct studies of non-medical products and systems.
This topic is relevant to the Boston UX community given the convergence of consumer and medical devices, as well as the rise of wearable technologies and the apps that interact with them. This presentation will cover the key aspects of HF/UE validation (a.k.a. ‘summative’) testing and what the FDA expects in the final HF/UE summary report.
Importantly, this session will consist of half presentation and half Q&A, with the audience driving the discussion toward current issues, questions, and challenges that are relevant to them.
An brief introduction to the clinical data management process is described in this slides. These slides provides you the information regarding the data evaluation in the clinical trials , edit checks and data review finally data locking,then the data is submitted to the concerned regulatory body.
This is a comprehensive report on medical devices interoperability in India
This report covers global developments in interoperability of medical devices
Medical devices – Quality management
systems – Requirements for regulatory
Purposes. ISO is an organization that develops Standards for use
worldwide.
ISO 13485 helps companies do their share in protecting
consumers and users of medical devices.
ISO 13485 Outlines criteria for a good Quality
Management System (QMS).
QMS criteria are good business practices ...
for example:
• Set Quality goals
• Ensure that regulations and other requirements are
understood and met
• Train employees
• Control your production processes
• Purchase from suppliers that can provide products that
meet your requirements
• Correct problems and make sure they do not happen again
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
Abbreviated New Drug Application (ANDA) Submission:
Introduction
Basic Generic Drug Requirements
Goals of ANDA
Basis of ANDA Submission
ANDA Forms and Submission Requirements
ANDA Review Process
CTD Triangle
Electronic Submissions
Checklist for ANDA submission (Module 1 to Module 5)
Veeva Systems Webinar: Driving Continuous Quality ImprovementsVeeva Systems
Watch the on-demand webinar here: https://go.veeva.com/driving-continuous-quality-improvements/on-demand
Building a strong foundation to drive continuous quality improvements requires connecting people, processes, and technology. Life sciences companies transforming quality management with this holistic approach have increased quality management efficiency by up to 50% and reduced paperwork by 90%.
Watch the webinar and learn how you can create such a foundation for your organization on an intelligent, data-driven, end-to-end digital platform. You will also hear real-world use cases of applying advanced technologies like AI to enable proactive quality management across all operational areas.
You will hear:
- Opportunities and recommendations to unify and streamline quality systems and processes
- Areas where modern-era technologies like cloud and AI can increase efficiency, optimize cost, and bring products to patients faster
- Real-world examples of how leading organizations are transforming quality management to drive continuous quality improvements.
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
In this presentation, Brandon May, freelance medical writer and owner of May Medical Communications, LLC, describes 5 types of medical writing.
Read the blog post that accompanies this slide deck at http://maymedcomm.com/5-different-types-of-medical-writing/
ISR explores eClinical technologies like CTMS, EDC, IRT, EMR, and eCOA in this infographic.
Learn more: http://www.isrreports.com/free-resources/eclinical-trends-tips-and-technology/
In this report, ISR leverages the insights and real-world experiences investigative sites have with electronic medical records (EMRs) and clinical trials. The report examines how sites currently use EMRs for various clinical trial activities and provides recommendations to improve trial efficiency.
This is a comprehensive report on medical devices interoperability in India
This report covers global developments in interoperability of medical devices
Medical devices – Quality management
systems – Requirements for regulatory
Purposes. ISO is an organization that develops Standards for use
worldwide.
ISO 13485 helps companies do their share in protecting
consumers and users of medical devices.
ISO 13485 Outlines criteria for a good Quality
Management System (QMS).
QMS criteria are good business practices ...
for example:
• Set Quality goals
• Ensure that regulations and other requirements are
understood and met
• Train employees
• Control your production processes
• Purchase from suppliers that can provide products that
meet your requirements
• Correct problems and make sure they do not happen again
Accelerating Patient Care with Real World EvidenceCitiusTech
Life sciences and pharma companies are evolving their strategies to utilize Real World Data (RWD) to demonstrate value of pharmaceutical and medical device innovations. Technology advancements at the point of care and improvements in data collection strategies have led to a significant increase in the availability of RWD in healthcare
Real World Evidence (RWE) can provide actionable patient insights and accelerates time to market of new medical products in order to gain competitive advantage
With the emergence of wearable technologies, Internet of Things (IOT), Cognitive Computing, Genomics, Blockchain, etc., future RWE data sources will become more diverse and extensive. This document introduces the concept of Real World Evidence studies in healthcare, describes the various data sources for performing real world analytics and illustrates the role of RWE in better patient care. It then summarizes challenges faced while performing RWE analytics with respect to regulatory compliance, data accessibility and sharing, analysis reporting, costs etc.
Abbreviated New Drug Application (ANDA) Submission:
Introduction
Basic Generic Drug Requirements
Goals of ANDA
Basis of ANDA Submission
ANDA Forms and Submission Requirements
ANDA Review Process
CTD Triangle
Electronic Submissions
Checklist for ANDA submission (Module 1 to Module 5)
Veeva Systems Webinar: Driving Continuous Quality ImprovementsVeeva Systems
Watch the on-demand webinar here: https://go.veeva.com/driving-continuous-quality-improvements/on-demand
Building a strong foundation to drive continuous quality improvements requires connecting people, processes, and technology. Life sciences companies transforming quality management with this holistic approach have increased quality management efficiency by up to 50% and reduced paperwork by 90%.
Watch the webinar and learn how you can create such a foundation for your organization on an intelligent, data-driven, end-to-end digital platform. You will also hear real-world use cases of applying advanced technologies like AI to enable proactive quality management across all operational areas.
You will hear:
- Opportunities and recommendations to unify and streamline quality systems and processes
- Areas where modern-era technologies like cloud and AI can increase efficiency, optimize cost, and bring products to patients faster
- Real-world examples of how leading organizations are transforming quality management to drive continuous quality improvements.
This presentation mainly deals with clinical development of biosimilar products. It also gives enough on non-clinical development so that the audience is well oriented.
In this presentation, Brandon May, freelance medical writer and owner of May Medical Communications, LLC, describes 5 types of medical writing.
Read the blog post that accompanies this slide deck at http://maymedcomm.com/5-different-types-of-medical-writing/
ISR explores eClinical technologies like CTMS, EDC, IRT, EMR, and eCOA in this infographic.
Learn more: http://www.isrreports.com/free-resources/eclinical-trends-tips-and-technology/
In this report, ISR leverages the insights and real-world experiences investigative sites have with electronic medical records (EMRs) and clinical trials. The report examines how sites currently use EMRs for various clinical trial activities and provides recommendations to improve trial efficiency.
In a unified eClinical infrastructure, formerly disparate clinical study systems are merged.
Users no longer work in “CTMS” or “eTMF”, but in a harmonized clinical infrastructure where a single source of truth is a given, and changes and additions automatically impact the appropriate data, documents and processes.
This presentation will show you what clinical unification is, its benefits and how it can be achieved.
IT Outsourcing (ITO) in the Life Sciences Industry - Service Provider LandscapeEverest Group
This report provides a comprehensive assessment of the service provider landscape for IT outsourcing (ITO) services in the life sciences industry. It maps 14 leading service providers on the Everest Group PEAK Matrix and includes detailed profiles of these service providers. This evaluation categorizes the service providers into Leaders, Major Contenders, and Emerging Players. It also identifies top three service providers as Star Performers, based on their year on year movement on the Matrix
IT Application Outsourcing (AO) in the Healthcare Provider Industry - Service...Everest Group
This report provides a comprehensive assessment of the service provider landscape for IT outsourcing (ITO) services in the healthcare provider industry. It maps 12 leading service providers on the Everest Group PEAK Matrix and includes detailed profiles of these service providers. This evaluation categorizes the service providers into Leaders, Major Contenders and Emerging Players and also identifies top three services providers as Star Performers, based on their year on year movement on the matrix
Japan Laboratory Informatics Market PPT: Growth, Outlook, Demand, Keyplayer A...IMARC Group
The Japan laboratory informatics market size is projected to exhibit a growth rate (CAGR) of 5.30% during 2024-2032.
More Info:- https://www.imarcgroup.com/japan-laboratory-informatics-market
Benefits of Using an EDC System
Contact info@trialjoin.com for more information about patient recruitment help, obtaining new studies or help with site management.
Medisolv offers comprehensive Quality Reporting and Management software that assists Eligible Hospitals and Professionals in addressing their electronic and abstracted measure needs. Our software solution, paired with our expert consultants, assist clients with their quality reporting requirements. As a part of our quality solution we offer submission services to CMS and The Joint Commission. Our Quality Reporting and Management solution is exclusively endorsed by the American Hospital Association.
Medisolv also offers Business Analytics solutions that feature automated daily EHR data extracts. Our platform provides management with the tools and analytics to improve performance.
Open Source Services Market by Product Type, Distribution Channel, End User 2...IMARC Group
The global open source services market size reached US$ 25.93 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 74.46 Billion by 2028, exhibiting a growth rate (CAGR) of 17.60% during 2023-2028.
More Info:- https://www.imarcgroup.com/open-source-services-market
Detailed Project Report on Cholesterol Testing System Manufacturing Unit SetupIMARC Group
The report provides a complete roadmap for setting up an cholesterol testing system manufacturing plant. It covers a comprehensive market overview to micro-level information such as unit operations involved, raw material requirements, utility requirements, infrastructure requirements, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, etc.
More Info:- https://www.imarcgroup.com/cholesterol-testing-system-manufacturing-plant-project-report
South Korea Green Data Center Market by Product Type, Distribution Channel, E...IMARC Group
The South Korea green data center market size is projected to exhibit a growth rate (CAGR) of 12.20% during 2024-2032.
More Info:- https://www.imarcgroup.com/south-korea-green-data-center-market
India DC Power Systems Market Forecast & Opportunities, 2014 – 2024| TechSci ...TechSci Research
According to www.techsciresearch.com latest report- India DC Power Systems Market By Type (Low Power (Below 4 kW), Medium Power (4.1-32 kW) & High Power (Above 32 kW)), By End User (Industrial, Commercial, Telecom and Others), Competition, Forecast & Opportunities, 2014 – 2024
Report URL- https://www.techsciresearch.com/report/india-dc-power-systems-market/4035.html
The 2014 CRASH Report finds applications built with either Agile or Waterfall methods alone are more susceptible to security, reliability, performance, and cost issues.
Electric Bus Manufacturing Plant Project .pptxrudrap2099
The report provides detailed insights into project economics, including capital investments, project funding, operating expenses, income and expenditure projections, fixed costs vs. variable costs, direct and indirect costs, expected ROI and net present value (NPV), profit and loss account, financial analysis, etc.
The specialized industry of collecting electronic patient-reported outcomes is increasing linearly, in part because global government regulators want to hear directly from the patient, and because the acceleration and availability of electronic collection (vs. paper collection) improves data quality and efficiencies for data analysis and trial management. This document will review the ePRO market, and outline the five ePRO methods what successfully support the collection of patient-reported data
Similar to EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015) (20)
Bioanalytical Labs Market Dynamics and Service Provider Performance (3rd Edit...Industry Standard Research
5 need-to-know facts from ISR's newest primary market research report on Bioanalytical Lab Service Providers. Staying on top of an entire marketplace is a tall order. Sponsors’ needs change, market trends come and go, providers merge, capabilities evolve. The bioanalytical lab space is no different. ISR keeps a finger on the pulse of the bioanalytical lab market to help both sponsors and providers stay current with market dynamics and anticipate changes that may be coming down the pike. These data can be used to plan for future resource requirements, develop outsourcing strategies, inform tactical/operational and strategic planning, enhance service offerings, and for organizational benchmarking.
The information in ISR’s Electronic Media Use in Academic Medical Center Patient Recruitment report sheds light on the benefits, challenges and strategies of electronic media use for clinical trial recruitment. We are currently in an era where Facebook, Twitter, and Google searches link all of us to a larger global community. Clinical sites are actively navigating how to apply these resources to connect with patients around the world. The report will help academic medical centers, site personnel and CRO/sponsors understand which channels and strategies will best help accomplish their recruitment goals, and which ones can be developed for increased success in this realm.
One aspect of personalized medicine is certain; it is
complicated. If you happen to have a highly scientific
background, you actually may be able to define the term.
However, if you polled five people very familiar with
personalized medicine, you should expect to hear five
different definitions. ISR wanted to understand where oncologists stand on the topic of personalized medicine. We interviewed 101 US based, board-certified oncologists to gather their views on
how familiar they are with personalized medicine, how they
are treating patients, what tests are being used and which
will be used more, and how their patient treatment regimens
could evolve in the future.
ISR interviewed 13 experienced Regulatory Affairs professionals at 11 of the Top 50 pharmaceutical companies to better understand the Regulatory Affairs function. ISR has designed this report to be used as a benchmarking tool for companies to compare their Regulatory Affairs functions to those of other organizations. Key takeaways include:
Identify how your company’s approach to Regulatory Affairs may be different from a typical industry approach and the benefits and drawbacks that may result
Gather information on unique Regulatory Affairs structures and best practices employed by other organizations, which may be used to improve or streamline the function
Compare your company’s Regulatory Affairs department size, structure, resources and approach to those of other companies
Learn more: https://goo.gl/
ISR’s “CRO Quality Benchmarking – Phase IV Service Providers” report provides pharmaceutical sponsors and service providers a Consumer Reports-style analysis of CRO quality. Respondents supplied performance ratings based on their own experiences with 44 Phase IV CROs, making this report the most comprehensive assessment of CRO service quality in the industry. Now in its 8th year, this report has become a crucial tool for sponsors looking to select a Phase IV CRO and for service providers seeking an experience-based evaluation of their strengths and weaknesses.
As pharmaceutical and biopharmaceutical companies increase their levels of external development and manufacturing, the need for unbiased information to support strategic business decisions continues to grow. In this report, ISR provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality across a series of 26 performance attributes specific to drug product manufacturing projects. In this Consumer Reports-style analysis, ISR presents data on 423 service encounters from 217 respondents who have been involved in outsourced fill finish projects in the past 18 months.
ISR interviewed 14 highly experienced decision-makers to better understand the Market Access function. These professionals shared their perspectives on a range of topics related to the Market Access function, including the role of Market Access within their organizations, the structure of the Market Access function, and the key challenges faced by Market Access. Where possible, ISR also collected information on departmental headcounts, budgets, and outsourcing volume.
As many blockbuster drugs reach their patent cliffs, pharmaceutical companies and their service providers are searching to make drug development a more efficient process. Here are just a few of the trends to look for in the coming years.
Learn more: http://bit.ly/1LSIgwJ
Over 30 years after the Orphan Drug Act was passed, orphan drugs continue to be a lucrative market for pharma companies. Although orphan diseases affect small populations, these treatments address a high unmet need and also benefit from commercially attractive pricing structures and additional regulatory benefits.
Full graphic: http://www.isrreports.com/free-resources/5408/
One in 77 women will be diagnosed with ovarian cancer. ISR examines risk factors, prevalence, and the prognosis of ovarian cancer in this infographic.
More at: http://www.isrreports.com/free-resources/ovarian-cancer-profile/
As of December 2014, the publicly traded CROs had added a combined $14 billion to the market in the prior two years. In this infographic, ISR examines the ever-growing CRO Capital Market. For more ISR research, visit www.ISRreports.com.
The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public CROs saw their stock prices rise as well. In 2014, the clinical development industry saw an increased shift toward Risk-Based Monitoring methodologies and an increased reliance on eClinical technologies.
More: http://bit.ly/1w9gIOn
Thyroid Cancer is the most rapidly increasing cancer in the U.S. with 62,980 new cases predicted in 2014. ISR explores common types, risk factors, symptoms, treatment, and future drug development in this infographic.
- See more at: http://www.isrreports.com/free-resources/thyroid-cancer/#sthash.86CeZZ0E.dpuf
Learn more: http://www.isrreports.com/free-resources/thyroid-cancer/
Medical Affairs, as a function, sits at a crossroads in the pharmaceutical industry. The department is expected to act as a bridge between the commercial and scientific arms of an organization. Medical Affairs is further tasked with being the conduit of information between the company and external stakeholders, bringing efficacy and safety data to the medical community as well as gathering insights from the medical community to share internally. All responsibilities must be undertaken while keeping in mind strict regulatory controls and ensuring that medical data are interpreted appropriately.
ISR has designed this report to be used as a benchmarking tool for companies to compare their Medical Affairs functions to those of Top 50 pharmaceutical organizations.
See more: http://bit.ly/medaffairs
Clinical development activity in perspective: A head-to-head comparison of ...Industry Standard Research
When you think about it, spending on phase I-IV services by pharma sponsors is roughly equivalent to revenue generated by CROs. One company’s expense is another company’s revenue. ISR wanted to see how the largest public CROs stacked up to the largest pharma companies in terms of their phase I-IV activities.
- See more at: http://www.isrreports.com/free-resources/clinical-development-activity-perspective/#sthash.7xWDch7f.dpuf
Lung Cancer is the leading cause of cancer death. It claims more lives each year than do colon, prostate, ovarian and breast cancers combined. ISR explores risk factors, treatment, and drug development in this infographic.
- See more at: http://www.isrreports.com/free-resources/3595/#sthash.f3suitGk.dpuf
GBM is the most common and most aggressive form of primary malignant brain tumor. This infographic from ISR explores the disease, treatment, and possibilities for the future.
In 2013, R&D spending remained relatively flat and the number of studies started by industry also remained about the same, but outsourcing penetration is increasing. There are now more realistic options for sponsors seeking to outsource large studies. There will be more competition for large studies and the large CROs depend on large studies for their growth.
As is the case with many industries, the use of technology has replaced in-person interaction within the medical field. While the US deploys almost 80,000 pharmaceutical Medical Representatives (MRs), that number has decreased 12% since last year. Call centers, tablets, and electronic, web-based product detailing are meeting the needs of these now-eliminated positions. In the US, all top 20 pharma companies use e-detailing. What impact will that have on the future of drug detailing? - See more at: http://www.isrreports.com/free-resources/future-hold-detailing-drug-reps/#sthash.mWMj033N.dpuf
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com